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The management of locally advanced rectal cancers, although has remarkably improved in
the last years, still remains a challenge. The results of recent European randomised trias
have marked a paradigm shift from the postoperative to preoperative CRT approach. How-
ever, this approach do not impact on the occurrence of distant metastases, disease-free
survival and overall survival, underlining the need for a more intensified approach. More-
over, the data of retrospective analysis have evidenced that an other critical point is the
selection of patients for whom a risk-adapted pre and postoperative treatment should be
delivered, considering that locally advanced rectal tumours are a widely heterogeneous
group of tumours. Therefore, a refinements of a multimodality therapy by an integrated
approach of a highly skilled multidisciplinary team is needed for a further improvement
of clinical management.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
During the last 20 years, the treatment of rectal cancer has
dramatically changed. The recognition that the involvement
of the circumferential resection margin (CRM) is the stron-
gest negative prognostic factor for local recurrence, and the
consequent wide adoption in the surgical technique of the
total mesorectal excision (TME) has resulted in a significant
decline of the local recurrence rate. Moreover, randomised
controlled trials in clinically resectable rectal cancer have
supported the role of preoperative short-course radiotherapy
(SRT), and of preoperative 5-fluorouracil (5-FU)-based chemo-
radiotherapy (CRT) in further reducing the risk of local recur-
rence, even in the setting of an optimal surgery, but neither
strategy has demonstrated to positively impact on the occur-er Ltd. All rights reserved
; fax: +39 081 5903821.
(A. Avallone).rence of distant metastases, disease-free survival and overall
survival, underlining the need for a more intensified
approach.
However, locally advanced rectal cancers are a widely het-
erogeneous group of tumours that may have quite different
prognostic implications. Therefore, the careful identification
of patients at high-risk of recurrence is a critical issue, be-
cause it is likely that not all patients need a primary and/or
intensified approach. Moreover, considering that not all tu-
mours respond uniformly to a preoperative treatment, and
the poor adherence of patients to a postoperative chemother-
apy, a risk-adapted strategy should be pursued also in the
postoperative setting. Hence, the management of locally ad-
vanced rectal cancers, although has remarkably improved in
the last years, still remains a challenge..
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approach
The results of recent European randomised trials on patients
with locally advanced rectal cancer have highlighted the low-
er risk of local recurrence when preoperative 5-FU-based CRT
was compared with preoperative long-course RT alone,1,2 or
postoperative CRT.3 Moreover, there were additional benefits
in favor of preoperative CRT, such as a greater sphincter pres-
ervation surgery, a better compliance with the planned treat-
ment and a lower incidence of acute and late toxicity. These
findings have marked a paradigm shift from the postoperative
to preoperative CRT approach.
SRT has also demonstrated to be an effective preoperative
treatment in resectable rectal cancer. The results of Dutch
CKVO 95-044 and MRC CR075 trials have clearly shown a sta-
tistically significant reduction in the rate of local recurrence,
and a 5% improvement in 3-year disease-free survival in the
MRC CR07 trial, when SRTwas combined with TME. However,
SRT has the drawback of not producing a tumour shrinkage,
and therefore it is unable to allow for a sphincter preservation
in patients who are initially the candidate to an abdomino-
perineal resection (APR); moreover, due to its short duration,
it is not suitable for combination with an effective cytotoxic
treatment. In addition, there is a strong concern that SRT
may cause more late complications, such as sexual dysfunc-
tions and fecal incontinence, and an increased risk of second
tumours.6,7
On the other hand, SRT compared to preoperative CRT did
not result in an inferior rate of sphincter preservation, and
appeared equally effective in preventing local recurrence in
the Polish trial.8 However, it should be noted that a postoper-
ative adjuvant chemotherapy was more frequently delivered
in the SRT arm (47% versus 31%, P = 0.006), as a consequence
of the greater downstaging effect of the preoperative CRT, and
this difference represents a confounding factor. Anyway, the
benefit observed in these preoperative strategies did not
translate in a significant reduction of the occurrence of dis-
tant metastases, and in an improvement of overall survival.
The data of retrospective analyses in patients with resect-
able rectal cancer have reported widely different recurrence-
free and overall survival rates according to both the T and N
extensions, raising the need of refining the selection of pa-
tients for different treatment strategies .9 Moreover, in addi-
tion to the T and N stages, the key role of the CRM
involvement in identifying patients with a poorer outcome,
not only in terms of local and distant recurrence, but also
as regards the overall survival, has clearly emerged in the last
few years.10 The worse prognosis of patients with low (less
than 5 cm from the anal verge) rectal cancer has also been as-
cribed to the higher frequency of a CRM involvement, occur-
ring for the natural ‘coning-in’ of the mesorectum in this
anatomic site.11 Interestingly, the data of the Dutch CKVO
95-04 and MRC CR07 trials have also demonstrated that a
postoperative RT or CRT cannot sufficiently compensate for
a positive CRM, supporting the need to achieve an R0 resec-
tion.5,12 In the light of these findings, the prediction of a
CRM involvement by a high resolution magnetic resonance
imaging (MRI) plays an important role, leading to a better def-inition of the patient’s prognosis, and avoiding unnecessary
and potentially harmful treatment.13 In this regard, it has
been demonstrated that an MRI-based strategy, intensifying
the preoperative treatment in the patients with a potential
involvement of CRM, resulted in a significant reduction of
pathologically positive CRM .14 Moreover, the recent introduc-
tion of new MRI contrast agents (like the ultra small super
paramagnetic iron oxide (USPIO) has shown that this tech-
nique may be very promising also for the detection of lymph
node metastases.15 Therefore, in the era of a preoperative ap-
proach, a staging with MRI should be mandatory for all pa-
tients with rectal cancer before any treatment decision is
taken, because it may reduce the risk of overtreatment for pa-
tients with an early-stage tumour, whilst improving the iden-
tification of patients with a high-risk of recurrence.
A variety of phase II trials have shown that an intensified
approach, combining different cytotoxic agents during preop-
erative pelvic radiotherapy in high-risk patients, led to a con-
sistent increase of the pathological response rate, and of
complete responses (pCR).16–20 Yet, a high downstaging and
pCR rate has also been achieved with a short intense regimen
of chemotherapy before preoperative CRT, but an unpredict-
able rate of toxic deaths (5%) was reported, indicating that
this approach should be used with caution, and restricted to
clinical trials.21
However, the flaw of most of these studies is due to the
heterogeneity of locally advanced rectal cancer patients in-
cluded in these series, and to the lack of a standardised clin-
ical and pathological assessment, which might have
contributed to the reported high pCR rates. Moreover, the
pCRs obtained after preoperative chemo-radiotherapy is not
yet a validated surrogate end-point for the long-term out-
come, whilst it remains to be defined whether an excellent
pathological response has a true impact on the natural his-
tory of the disease, or it is merely associated with more
favourable pretreatment characteristics of the patient and/
or of the tumour. Furthermore, few studies have reported
the long-term outcomes and the late toxicity of the combined
treatment. Therefore, we still need prospective data to con-
firm that an intensified treatment of chemo-radiotherapy,
achieving a higher rate of pCR, will also positively affect the
overall survival of patients. Ongoing clinical trials will provide
some insight into this important issue.
3. Selection of patients for the postoperative
treatment
An other critical point, in the era of the preoperative ap-
proach, is the selection of patients for whom a risk-adapted
postoperative chemotherapy should be delivered, considering
that not all tumours respond uniformly to the preoperative
treatment, and taking also into account the poor patient’s
compliance to a postoperative chemotherapy. Indeed, recent
results of the EORTC 22921 trial failed to demonstrate a signif-
icant impact of postoperative chemotherapy on survival,
although a late difference seemed to emerge at approximately
2 years for disease-free survival and at 4 years for overall sur-
vival.1 This trend suggested that certain subgroups of patients
may benefit from postoperative chemotherapy. A recently
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tients showing a pathological downstaging after the preoper-
ative treatment also benefited from the postoperative 5-FU-
based chemotherapy.22 However, this conclusion was drawn
from an unplanned and underpowered subset analysis. Fur-
thermore, the EORTC trial provided the intriguing finding that
postoperative chemotherapy compensated for the lack of
preoperative chemotherapy on local recurrence. Indeed, the
5-year local recurrence was 17.1% for patients who did not
receive any chemotherapy, whilst it was about 8% for those
who received some chemotherapy at any time.
A prognostic significance of the tumour regression grade
(TRG) has been reported in a cohort of 406 rectal cancer pa-
tients treated with preoperative chemo-radiotherapy in the
CAO/ARO/AIO 94 trial.23 On the other hand, although the
TRG was proven in this series to be prognostically valuable
at the univariate analysis, a ypN+ resulted the strongest prog-
nostic factor in the multivariate model.
The analysis of outcomes in the Polish trial has suggested
that the persistence of nodal involvement after CRT could be
due to chemo-radioresistance, resulting in the association
with a greater potential for developing local recurrence and
distant metastases.24 The relevance of ypN has also been re-
ported in a series of 95 patients treated with preoperative 5-
FU-based chemo-radiotherapy followed by an R0 resection
(and postoperative 5-FU-chemotherapy in 65 patients), in
which only the ypN status resulted a significant prognostic
parameter.25 Interestingly, these investigators found that
the 3-year disease-free survival for patients with ypN0 was
excellent, regardless of whether they had received or not
the postoperative chemotherapy (87.5% versus 87.7%),
whereas patients with ypN2 status had a poor 3-year dis-
ease-free survival (30%) despite the postoperative chemo-
therapy. In conclusion, one might speculate that some
patients likely do not require a postoperative treatment at
all, whilst other patients actually need a more effective ap-
proach. Moreover, a recent study suggested that, after preop-
erative CRT, the proximal lymph node involvement was
associated with a high incidence of metastatic disease at
the time of surgery, indicating the prognostic importance of
the distribution as well as of the number of lymph nodes
involved.26
Themajor prognostic role of the pathological CRM involve-
ment was also recently confirmed after a preoperative CRT. In
that study, patients with borderline resectable or unresectable
locally advanced rectal cancer were treated with preoperative
long-course pelvic radiotherapy plus 5-FU-based chemother-
apy: a significant difference was found both in 3-year dis-
ease-free survival (52% versus 9%, P < 0.001) and overall
survival (64% versus 25%, P < 0.0001) between patients show-
ing a pathologically negative CRM and those who did not.27
A careful histological assessment of the surgical speci-
mens has been demonstrated to be a crucial point to obtain
a correct prognostic information. Several studies have under-
lined that an accurate lymph node retrievement and assess-
ment is mandatory, particularly when the tumour is staged
as T3N0.28 Moreover, a careful pathologic evaluation allows
to assess the quality of surgery,29 may be helpful in planning
the post-surgical treatment, and may facilitate interstudy
comparisons.Finally, the possibility of a ‘waiting and see’ policy should
be remembered, with surgery omission when a complete clin-
ical response is obtained after preoperative CRT. However,
there are a number of criticisms about this approach, which
is based on incomplete and unclear data, also considering
the difficulties of identifying patients that could avoid the sur-
gical resection on the basis of a clinical and pathological
(biopsy) assessment.30
However, an organ-sparing approach remains intriguing.
In this regard, an interesting role in early predicting the tu-
mour response has recently been advocated for the 18F-FDG
PET.31 This imaging technique, performed 12 days after the
beginning of CRT, has been demonstrated to predict the path-
ological response. These results are provocative, because an
early identification of non-responder patients might prompt
alternative treatment strategies, whilst allowing to plan a
conservative surgical approach in patients with a prediction
of a good pathological response. However, these new ap-
proaches require to be validated in large prospective studies.
4. Conclusion
In the last few years the common use of TME, and the shift
from a postoperative to a preoperative chemo-radiotherapy
approach, have substantially reduced the risk of local recur-
rence in locally advanced rectal cancer. Chemotherapy has
been shown to play a relevant role in the management of this
disease, but the integration of novel cytotoxic drugs and bio-
logic agents in combined approaches should be widely ex-
plored, in an attempt to improve the disease downstaging
and to control the distant spread. However, the key for a fur-
ther improvement of the clinical management will be the
accurate assessment of the disease, based not only on the
clinical and pathological features but also on molecular and
genetic markers,32 for a ‘risk-adapted’ strategy of treatment.
Moreover, early prediction of pathological tumour response
by genomic approaches and imaging modalities could lead
to further tailoring the rectal cancer management. Refine-
ments of a multimodality therapy, in order to maximise the
potential for cure and minimize the impact on the patients
quality of life, will only derive from an integrated approach
of a highly skilled multidisciplinary team.
Conflict of interest statement
None declared.R E F E R E N C E S1. Bosset JF, Collette L, Calais G, et al. Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med
2006;355:1114–23.
2. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative
radiotherapy with or without concurrent fluorouracil and
leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin
Oncol 2006;24:4620–5.
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus
postoperative chemoradiotherapy for rectal cancer. N Engl J
Med 2004;351:1731–40.
E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 7 0 –7 3 734. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative
radiotherapy combined with total mesorectal excision for
resectable rectal cancer. N Engl J Med 2001;345:638–46.
5. Sebag-Montefiore D, Steel R, Quirke P, et al. Routine short
course pre-op radiotherapy or selective post-op
chemoradiotherapy for resectable rectal cancer? Preliminary
results of the MRC CR07 randomized trial. J Clin Oncol
2006;24(Suppl. 18) [abstract 3511].
6. Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-
term preoperative radiotherapy on health-related quality of
life and sexual functioning in primary rectal cancer: report of
a multicenter randomized trial. J Clin Oncol 2005;23:1847–58.
7. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of
short-course preoperative radiotherapy combined with total
mesorectal excision for rectal cancer: increased bowel
dysfunction in irradiated patients – a Dutch colorectal cancer
group study. J Clin Oncol 2005;23:6199–206.
8. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W,
Bebenek M, Kryj M. Long-term results of a randomized trial
comparing preoperative short-course radiotherapy with
preoperative conventionally fractionated chemoradiation for
rectal cancer. Br J Surg 2006;93:1215–23.
9. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N
stage and treatment on survival and relapse in adjuvant rectal
cancer: a pooled analysis. J Clin Oncol 2004;22:1785–96.
10. Nagtegaal ID, Marleen JEM. Combinations of tumor and
treatment parameters are more discriminative for prognosis
than the present TNM system in rectal cancer. J Clin Oncol
2008;25:1647–50.
11. Nagtegaal ID, van de Velde CJ, Marijnen CA, van Krieken JH,
Quirke P. Low rectal cancer: a call for a change of approach in
abdominoperineal resection. J Clin Oncol 2005;23:9257–64.
12. Marijnen CA, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy
does not compensate for positive resection margins in rectal
cancer patients: report of a multicenter randomized trial. Int J
Radiat Oncol Biol Phys 2003;55:1311–20.
13. Mercury Study Group. Diagnostic accuracy of preoperative
magnetic resonance imaging in predicting curative resection
of rectal cancer: prospective observation study. BMJ
2007;333:779–84.
14. Burton S, Brown G, Daniels IR, Norman AR, Mason B,
Cunningham D. MRI directed multidisciplinary team
preoperative treatment strategy: the way to eliminate positive
circumferential margins? Br J Cancer 2006;94:351–7.
15. Beets GL, Lahaye M, Engelen SME, et al. Can we predict the
nodal status in primary rectal cancer accurately with USPIO
MRI? EJC 2007;5(Suppl. 4) [abstract 3005].
16. Mehta VK, Cho C, Ford JM, et al. Phase II trial of preoperative
3D conformal radiotherapy, protracted venous infusion 5-
fluorouracil, and weekly CPT-11, followed by surgery for
ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys
2003;55:132–7.
17. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W,
Schmoll HJ, Sauer R. Phase I/II trial of capecitabine,
oxaliplatin, and radiation for rectal cancer. J Clin Oncol
2003;21:3098–104.
18. Aschele C, Friso ML, Pucciarelli S, et al. A phase I–II study of
weekly oxaliplatin, 5-fluorouracil continuous infusion and
preoperative radiotherapy in locally advanced rectal cancer.
Ann Oncol 2005;16:1140–6.
19. Avallone A, Delrio P, Guida C, et al. Biweekly oxaliplatin,
raltitrexed, 5-fluorouracil and folinic acid combinationchemotherapy during preoperative radiation therapy for
locally advanced rectal cancer: a phase I–II study. Br J Cancer
2006;94:1809–15.
20. Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-
Montefiore D. A phase I/II study of irinotecan when added to
5-fluorouracil and leucovorin and pelvic radiation in locally
advanced rectal cancer: a Colorectal Clinical Oncology Group
Study. Br J Cancer 2007;96:551–8.
21. Chau I, Brown G, Cunningham D, et al. Neoadjuvant
capecitabine and oxaliplatin followed by synchronous
chemoradiation and total mesorectal excision in magnetic
resonance imaging-defined poor-risk rectal cancer. J Clin Oncol
2006;24:668–74.
22. Collette L, Bosset JF, den Dulk M, et al. Patients with curative
resection of T3-4 rectal cancer after preoperative
radiotherapy or radiochemotherapy: does anybody benefit
from adjuvant fluorouracile-based chemotherapy? A trial of
the European Organisation for Research and Treatment of
Cancer Radiation Oncology Group. J Clin Oncol
2007;25:4379–86.
23. Rodel C, Martus P, Papadoupolos T, et al. Prognostic
significance of tumor regression after preoperative
chemoradiotherapy for rectal cancer. J Clin Oncol
2005;23:8688–96.
24. Bujko K, Michalski WMS, Kepka L, et al. Association
between pathologic response in metastatic lymph nodes
after preoperative chemoradiotherapy and risk of distant
metastases in rectal cancer: an analysis of outcomes in a
randomized trial. Int J Radiat Oncol Biol Phys
2007;67:369–77.
25. Fietkau R, Barten M, Klautke G, et al. Postoperative
chemotherapy may not be necessary for patients with ypN0-
category after neoadjuvant chemoradiotherapy of rectal
cancer. Dis Colon Rectum 2006;49:1284–92.
26. Leibold T, Shia J, Ruo L, et al. Prognostic implication of the
distribution of lymph node metastases in rectal cancer after
neoadjuvant chemoradiotherapy. J Clin Oncol 2008;26:2106–11.
27. Mawdsley S, Glynne-Jones R, Grainger J, et al. Can
histopathologic assessment of circumferential margin after
preoperative pelvic chemoradiotherapy for T3-T4 rectal
cancer predict for 3-year disease-free survival? Int J Radiat
Oncol Biol Phys 2005;63:745–52.
28. Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of
number of nodes retrieved on outcome in patients with rectal
cancer. J Clin Oncol 2001;19:157–63.
29. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn
P, Quirke P, van Krieken JH. Macroscopic evaluation of
rectal cancer resection specimen: clinical significance of
the pathologist in quality control. J Clin Oncol
2002;20:1729–34.
30. Glynne-Jones R, Wallace M, Livingstone JIL, Meyrich-Thomas
J. Complete clinical response after preoperative
chemoradiation in rectal cancer: is a ‘‘wait and see’’ policy
justified? Dis Colon Rectum 2008;51:10–20.
31. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early
predictor of pathologic tumor response to preoperative
radiochemotherapy in locally advanced rectal cancer. J Nucl
Med 2006;47:1241–8.
32. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness
of gene expression profiling for response prediction of rectal
adenocarcinomas to preoperative chemoradiotherapy. J Clin
Oncol 2005;23:1826–38.
